These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4036982)

  • 1. Polymyalgia rheumatica. Duration of therapy and long-term outcome.
    Ayoub WT; Franklin CM; Torretti D
    Am J Med; 1985 Sep; 79(3):309-15. PubMed ID: 4036982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.
    Salvarani C; Macchioni P; Manzini C; Paolazzi G; Trotta A; Manganelli P; Cimmino M; Gerli R; Catanoso MG; Boiardi L; Cantini F; Klersy C; Hunder GG
    Ann Intern Med; 2007 May; 146(9):631-9. PubMed ID: 17470831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial.
    Caporali R; Cimmino MA; Ferraccioli G; Gerli R; Klersy C; Salvarani C; Montecucco C;
    Ann Intern Med; 2004 Oct; 141(7):493-500. PubMed ID: 15466766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
    van der Veen MJ; Dinant HJ; van Booma-Frankfort C; van Albada-Kuipers GA; Bijlsma JW
    Ann Rheum Dis; 1996 Apr; 55(4):218-23. PubMed ID: 8733437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Appearance of giant cell arteritis 6 years after the 1st manifestation of polymyalgia rheumatica].
    Felder M; Velvart M; Fehr K; Böni A; Wagenhäuser FJ
    Z Rheumatol; 1981; 40(6):240-2. PubMed ID: 7331551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica.
    Gabriel SE; Sunku J; Salvarani C; O'Fallon WM; Hunder GG
    Arthritis Rheum; 1997 Oct; 40(10):1873-8. PubMed ID: 9336424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis.
    Narváez J; Nolla-Solé JM; Clavaguera MT; Valverde-García J; Roig-Escofet D
    J Rheumatol; 1999 Sep; 26(9):1945-52. PubMed ID: 10493675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyalgia rheumatica and giant cell arteritis.
    Unwin B; Williams CM; Gilliland W
    Am Fam Physician; 2006 Nov; 74(9):1547-54. PubMed ID: 17111894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of the usefulness of a protocol with high-dose methotrexate in polymyalgia rheumatica: Results of a single-center cohort of 100 patients.
    Quartuccio L; Gregoraci G; Isola M; De Vita S
    Geriatr Gerontol Int; 2018 Sep; 18(9):1410-1414. PubMed ID: 29978586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study.
    González-Gay MA; García-Porrúa C; Vázquez-Caruncho M; Dababneh A; Hajeer A; Ollier WE
    J Rheumatol; 1999 Jun; 26(6):1326-32. PubMed ID: 10381051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid-responsive electromyographic abnormalities in polymyalgia rheumatica.
    Bromberg MB; Donofrio PD; Segal BM
    Muscle Nerve; 1990 Feb; 13(2):138-41. PubMed ID: 2314416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Azathioprine in the treatment of temporal arteritis and polymyalgia rheumatica].
    Lovschall S
    Ugeskr Laeger; 1977 Oct; 139(44):2618-20. PubMed ID: 145049
    [No Abstract]   [Full Text] [Related]  

  • 13. Corticosteroid requirements in polymyalgia rheumatica.
    Weyand CM; Fulbright JW; Evans JM; Hunder GG; Goronzy JJ
    Arch Intern Med; 1999 Mar; 159(6):577-84. PubMed ID: 10090114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of dapsone in the treatment of Horton's disease and polymyalgia rheumatica].
    Doury P; Fabresse FX; Pattin S; Eulry F; Celton H; Larroque P
    Ann Med Interne (Paris); 1984; 135(1):31-5. PubMed ID: 6703568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study.
    Chuang TY; Hunder GG; Ilstrup DM; Kurland LT
    Ann Intern Med; 1982 Nov; 97(5):672-80. PubMed ID: 6982645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Care Vasculitis: Polymyalgia Rheumatica and Giant Cell Arteritis.
    Pioro MH
    Prim Care; 2018 Jun; 45(2):305-323. PubMed ID: 29759126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.
    Salvarani C; Boiardi L; Macchioni P; Rossi F; Tartoni P; Casadei Maldini M; Mancini R; Beltrandi E; Portioli I
    Ann Rheum Dis; 1995 Aug; 54(8):640-4. PubMed ID: 7677440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis.
    Bahlas S; Ramos-Remus C; Davis P
    J Rheumatol; 1998 Jan; 25(1):99-104. PubMed ID: 9458211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of polymyalgia rheumatica: a systematic review.
    Hernández-Rodríguez J; Cid MC; López-Soto A; Espigol-Frigolé G; Bosch X
    Arch Intern Med; 2009 Nov; 169(20):1839-50. PubMed ID: 19901135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis.
    Muratore F; Pipitone N; Hunder GG; Salvarani C
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S86-92. PubMed ID: 24129145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.